Strikingly, these studies found that both genetic deletion and pharmacological blockade of mGlu5 reduced the presence of AD pathology, including Aβ oligomers and plaques, (Hamilton et al., 2014; Hamilton et al., 2016), and decreased synaptic loss and increased synaptic density (Um et al., 2013). The gene discussed is GRM5; the disease is Alzheimer disease.